Antimicrobials therapy of anaerobic infections

References

• Hentges DJ. The anaerobic microflora of the human body. Clin Infect Dis. 1993;16(4):S175–80.
   PubMedGoogle Scholar
• Brook I. Anaerobic infections diagnosis and management. New York: Informa Healthcare USA, Inc; 2007.
   Google Scholar
• Finegold SM. Anaerobic bacteria in human disease. New York: Academic Press; 1977.
   Google Scholar
• Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth-KTL anaerobic bacteriology manual. 6th edn. Belmont, CA: Star Publishing; 2002.
   Google Scholar
• Nagy E. Anaerobic infections: update on treatment considerations. Drugs. 2010;70(5):841–58.
   PubMedGoogle Scholar
• Citron DM, Hecht DW. Susceptibility test methods: anaerobic bacteria. In: Versalovic J, editor. Manual of clinical microbiology. 10th edn. Washington, DC: American Society for Microbiology Press; 2010; p. 1204–14.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 8th edn. Wayne, PA: Clinical and Laboratory Standards Institute [CLSI Document M11-A9]; 2012.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty second informational supplement. Wayne, PA: CLSI [CLSI Document M100-S22]; 2012.
   Google Scholar
• Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9):2819–28.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Goldman PJ, Goldman RJ. National survey of anaerobic culture and susceptibility methods: III. Anaerobe. 2008;14(2):68–72.
   PubMed Web of Science ®Google Scholar
• Sherwood JE, Fraser S, Citron DM, Wexler H, Blakely G, Jobling K, et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe. 2011;17(4):152–5.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe. 2011;17(4):147–51.
   PubMed Web of Science ®Google Scholar
• Brook I. Antimicrobial treatment of anaerobic infections. Expert Opin Pharmacother. 2011;12:1691–707.
   PubMed Web of Science ®Google Scholar
• Wexler HM. Bacteroides - the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621.
   PubMed Web of Science ®Google Scholar
• Busch DF, Kureshi LA, Sutter VL, Finegold SM. Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins. Antimicrob Agents Chemother. 1976;10(6):713–20.
   PubMedGoogle Scholar
• Acuna C, Rabasseda X. Amoxicillin-sulbactam: a clinical and therapeutic review. Drugs Today (Barc). 2001;37:193–210.
   PubMed Web of Science ®Google Scholar
• Finegold SM. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents. 1999;12(Suppl 1):S9–14.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(1):133–64.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(8):1373–406.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I and part II. Clin Microbiol Newsletter. 2011;33(1):1–14.
   Google Scholar
• Strehl E, Kees F. Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use. Drugs. 2000;59(Suppl 3):9–18.
   PubMed Web of Science ®Google Scholar
• Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother. 1976;10:736–52.
   PubMed Web of Science ®Google Scholar
• Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis. 2004;39(1):92–7.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Cole RE, Rangel DM, Seid AS, Ostovari MO. Cefoxitin in the treatment of aerobic/anaerobic infections: prospective correlation of in vitro susceptibility methods with clinical outcome. Hosp Pract (Off Ed). 1990;25(Suppl 4):38–45.
   PubMedGoogle Scholar
• Goldstein EJC, Citron DM, Merriam CV, Abramson MA. Infections after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. Surg Infect. 2009;10(1):111–8.
   PubMed Web of Science ®Google Scholar
• Itani KM, Wilson SE, Awad SS, Tomassini JE, Abramson MA. Ertapenem versus cefotetan prophylaxis in colorectal surgery. N Engl J Med. 2006;355(2):2640–51.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B; DRAGON Study Team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents. 2009;34(5):439–45.
   PubMed Web of Science ®Google Scholar
• Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc. 1999;74(3):420–34.
   PubMedGoogle Scholar
• Aldridge K, Aldridge KE, Ashcraft D, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group. Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 2001;45(4):1238–43.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Depestel DD, Doripenem. Clin Infect Dis. 2009;49(3):291–8.
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012;39(1):11–15.
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli. Antimicrob Agents Chemother. 1991;35(11):2410–4.
   PubMed Web of Science ®Google Scholar
• Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14(12):1102–11.
   PubMed Web of Science ®Google Scholar
• Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs. 2005;65(15):2151–78.
   PubMed Web of Science ®Google Scholar
• Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother. 2008;52(9):3161–8.
   PubMed Web of Science ®Google Scholar
• Wexler HM. Susceptibility testing of anaerobic bacteria: myth, magic, or method? Clin Microbiol Rev. 1991;4(4):470–84.
   PubMed Web of Science ®Google Scholar
• Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol. 2005;5(5):452–8.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC, Spangler SK, Pankuch GA, Philippon A, Jacobs MR, Shiman R, et al. Characterization of a beta-lactamase from Clostridium clostridioforme. J Antimicrob Chemother. 1994;33(1):33–40.
   PubMed Web of Science ®Google Scholar
• Pumbwe L, Chang A, Smith RL, Wexler HM. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J Antimicrob Chemother. 2006;58(3):543–8.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis. 2010;50(Suppl 1):S26–S33.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Supran S, Cuchural GJ Jr, Finegold S, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother. 1999;43(10):2417–22.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein EJ, Finegold SM, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis. 2002;35:S126–34.
   Web of Science ®Google Scholar
• Hecht DW, Osmolski JR, O'Keefe JP. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis. 1993;16(Suppl 4):S357–60.
   PubMedGoogle Scholar
• Thadepalli H, Gorbach SL, Bartlett JG. Apparent failure of chloramphenicol in anaerobic infections. Obstet Gynecol Surg. 1978;35(5):334–5.
   Google Scholar
• Balbi HJ. Chloramphenicol: a review. Pediatr Rev. 2004;25(8):284–8.
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet. 1998;35(3):223–46.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother. 1999;43(6):1469–74.
   PubMed Web of Science ®Google Scholar
• Williams JD, Maskell JP, Shain H, Chrysos G, Sefton AM, Fraser HY. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother. 1992;30(1):27–37.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Lewis RP, Sutter VL, Finegold SM. Treatment for anaerobic pleuropulmonary and soft-tissue Infections with erythromycin. JAMA. 1979;242(5):435–8.
   PubMed Web of Science ®Google Scholar
• Sanai Y, Persson GR, Starr JR, Luis HS, Bernardo M, Leitao J, et al. Presence and antibiotic resistance of Porphyromonas gingivalis. Prevotella intermedia, and Prevotella nigrescens in children. J Clin Periodontol. 2002;29(10):929–34.
   PubMed Web of Science ®Google Scholar
• Feigin RD, Pickering LK, Anderson D, Luis HS, Bernardo M, Leitao J, et al. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics. 1975;55(10):213–23.
   PubMedGoogle Scholar
• Klainer AS, Clindamycin. Med Clin North Am. 1987;71(6):1169–75.
   PubMed Web of Science ®Google Scholar
• Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet. 1990;19(4):280–318.
   PubMed Web of Science ®Google Scholar
• Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey  HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol. 1972;12(7):259–62.
   Web of Science ®Google Scholar
• Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med. 1999;341(22):1690–1.
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile - associated diarrhea: a review. Arch Intern Med. 2001;161(4):525–33.
   PubMedGoogle Scholar
• Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010;11(1):79–109.
   PubMed Web of Science ®Google Scholar
• Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes, microbiological and clinical aspects. Anaerobe. 2006;12(2):207–10.
   PubMed Web of Science ®Google Scholar
• Chow AW, Patten V, Guze LB. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore forming Gram-positive bacilli. J Infect Dis. 1975;131(2):182–5.
   PubMed Web of Science ®Google Scholar
• Rustia M, Shubik P. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT)BR rats. J Natl Cancer Inst. 1979;63(6):863–8.
   PubMedGoogle Scholar
• Cohen SM, Ertürk E, Von Esch AM, Crovetti AJ, Bryan GT. Carcinogenicity of 5-nitrofurans, 5-nitroimidazoles, 4-nitrobenzenes, and related compounds. J Natl Cancer Inst. 1973;51(2):403–17.
   PubMedGoogle Scholar
• Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N Engl J Med. 1979;301(10):519–22.
   PubMed Web of Science ®Google Scholar
• Loöfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Inf Dis. 2010;50(Supp. 1):s16–23.
   PubMed Web of Science ®Google Scholar
• Brook I. Treatment of anaerobic infections in children with metronidazole. Dev Pharmacol. 1983;6(3):187–98.
   PubMedGoogle Scholar
• Sørensen HT, Larsen H, Jensen ES, Thulstrup AM, Schønheyder HC, Nielsen GL, et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother. 1999;44(6):854–5.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother. 2006;50(10):3507–13.
   PubMed Web of Science ®Google Scholar
• Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In  vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother. 2004;48(2):1034–6.
   PubMed Web of Science ®Google Scholar
• Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60(12):1662–7.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Quinolone activity against anaerobes. Drugs. 1999;58(1):60–4.
   PubMed Web of Science ®Google Scholar
• Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48(3):1012–6.
   PubMed Web of Science ®Google Scholar
• Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis. 2006;42(11):1598–607.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother. 2006;50(1):148–55.
   PubMed Web of Science ®Google Scholar
• Oh H, Hedberg M, Edlund C. Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group. Anaerobe. 2002;8(3):277–82.
   Google Scholar
• Goldstein EJC, Citron DM, Solomkin J, Alder JD. Clinical efficacy and correlation of clinical outcomes with the in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53(11):1074–80.
   PubMed Web of Science ®Google Scholar
• Tyrrell KL, Citron DM, Warren YA, Goldstein EJ. In-vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother. 2012;56(4):2194–7.
   PubMed Web of Science ®Google Scholar
• Finch RG. Antibacterial activity of quinupristin/dalfopristin. Ration Clin Use Drugs. 1996;51(1):31–7.
   Google Scholar
• Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am. 2009;89(2):421–37.
   PubMed Web of Science ®Google Scholar
• Brook I, Gober E. Emergence of beta-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin Pediatr. 1984;23(6):338–41.
   PubMed Web of Science ®Google Scholar
• Katsandri A, Papaparaskevas J, Pantazatou A, Petrikkos GL, Thomopoulos G, Houhoula DP, et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J Clin Microbiol. 2006;44(9):3465–7.
   PubMed Web of Science ®Google Scholar